Lucigen to Seek FDA Emergency Use Approval for Isothermal Point-of-Care Ebola Test | GenomeWeb

NEW YORK (GenomeWeb) – Using fever to screen for Ebola casts a wide net, while standard RT-PCR requires many hours and expert technicians. Now, Madison, Wisc.-based Lucigen is accelerating development of a one-hour molecular assay to amplify and detect Ebola virus in decentralized settings like airports and emergency rooms.

The firm is currently pursuing US Food and Drug Administration Emergency Use Authorization for its point-of-care rapid Ebola diagnostic. The test relies on isothermal PCR and does not require extensive biosafety containment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.